Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (NYSE American: AIM) has announced the pricing of a $8.0 million public offering. The offering consists of 2,000,000 shares of common stock (or pre-funded warrants), along with Class E and Class F warrants, priced at $4.00 per share.

The offering includes Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with a $4.00 exercise price. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close around July 30, 2025.

AIM ImmunoTech (NYSE American: AIM) has reported positive mid-year data from its Phase 2 DURIPANC study, evaluating the combination of Ampligen® (rintatolimod) with AstraZeneca's Imfinzi® (durvalumab) for treating metastatic pancreatic cancer patients.

The study, conducted in collaboration with AstraZeneca and Erasmus Medical Center, has enrolled 14 out of 25 planned subjects. Key findings include: no significant toxicity, approximately 21% of patients showing PFS >6 months, and 64% of eligible patients achieving OS >6 months. The trial builds on previous successful results of Ampligen as a monotherapy in over 50 pancreatic cancer patients.

AIM has secured intellectual property protection through a U.S. patent extending to 2039 and orphan drug designations in both the U.S. and EU for Ampligen in pancreatic cancer treatment.

AIM ImmunoTech (NYSE American: AIM) announced a presentation at the U.S.-Poland Science and Technology Symposium 2025 featuring Dr. Pawel Kalinski's discussion on the company's drug Ampligen. The presentation, held from June 17-20, 2025, focused on the potential of private-public partnerships in developing oncology treatments.

Dr. Kalinski, a senior investigator for multiple Ampligen oncology studies, highlighted opportunities for expansion in the United States and Eastern European countries through initiatives like the Translational Research Cancer Centers Consortium. CEO Thomas K. Equels will pursue potential clinical partnerships and licensing agreements in Europe, particularly in Poland, at the upcoming Marie Sklodowska-Curie Symposia in September 2025.

AIM ImmunoTech has received a warning notification from NYSE American due to noncompliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of negative $3.9 million as of March 31, 2025, and has experienced losses in the past five fiscal years. NYSE American requires stockholders' equity of $4.0 million for companies with losses in three of four recent fiscal years, and $6.0 million for those with losses in five recent fiscal years. This follows a previous warning issued in December 2024. AIM has submitted a compliance plan that was accepted by NYSE American, giving the company until June 11, 2026, to meet requirements. The company's stock continues trading under symbol AIM, and the notice does not affect its business operations or SEC reporting requirements.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the resumption of trading of its common stock on the NYSE American exchange effective June 17, 2025. The company's shares are trading under the ticker symbol 'AIM' with CUSIP number 00901B303. The resumption of trading on NYSE American, one of the major U.S. stock exchanges, marks an important milestone for the company's market presence.

AIM ImmunoTech has secured a significant U.S. patent (No. 12312376) for manufacturing therapeutic double-stranded RNA (dsRNA) products, including Ampligen, extending protection until 2041. This patent complements AIM's existing portfolio covering Ampligen's manufacture, composition, and therapeutic applications. The company's IP portfolio includes patents for treating cancer (expires 2039), Post-COVID fatigue (expires 2042), and endometriosis (expires 2040). Additionally, AIM holds multiple Orphan Drug Designations from FDA and EMA, providing 7-10 years of market exclusivity post-approval for conditions including Metastatic Melanoma, Renal Cell Carcinoma, Pancreatic Adenocarcinoma, Ebola Virus Disease, Chronic Fatigue Syndrome, and HIV.

AIM ImmunoTech (NYSE American: AIM) announced that NYSE Regulation has withdrawn its delisting determination and will lift the trading suspension of the company's common stock. The decision comes after the company's stock price rose above the minimum threshold required by Section 1003(f)(v) of the NYSE American Company Guide. Trading of AIM's common stock is set to resume on the NYSE American on Tuesday, June 17, 2025, under the symbol 'AIM' with CUSIP 00901B303. This development marks a significant turnaround for the company, ensuring its continued listing on a major exchange.

AIM ImmunoTech (NYSE: AIM) has announced a 1-for-100 reverse stock split effective June 12, 2025. The primary objective is to boost the company's per-share market price to regain compliance with NYSE American's Listing Qualifications. The split was approved by stockholders at a Special Meeting on April 30, 2025. Following the split, the company's OTC Pink ticker will temporarily change to AIMID for 20 trading days. Stockholders will receive cash for any fractional shares post-split. The company's common stock will maintain its $0.001 par value but will be assigned a new CUSIP number: 00901B303.

AIM ImmunoTech (NYSE: AIM) presented clinical trial data for its drug Ampligen at the Annual Meeting of the American Association of Immunologists. Dr. Pawel Kalinski's presentation highlighted Ampligen's unique two-level selectivity when combined with PD-1 blockade or chemotherapy. The drug demonstrated the ability to: 1. Selectively induce CTL-attracting chemokines without triggering counterproductive Treg-attracting chemokines 2. Preferentially activate cancer tissues over healthy tissues The research showed that Ampligen's selective impact on tumor microenvironment stems from its ability to avoid helicase-dependent activation of NFkB, differentiating it from poly-I:C and other TLR ligands.